Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Severe Hypertriglyceridemia (SHTG) – Initial Baseline data from an Ongoing Phase 2 Study

Background/Synopsis: Fibroblast growth factor 21 (FGF21) is an endogenous metabolic hormone that regulates energy expenditure, lipid, and carbohydrate metabolism. BIO89-100, a glycoPEGylated FGF21 analog, is currently being evaluated in ENTRIGUE, a “Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety in Subjects with Severe Hypertriglyceridemia.”